Lipid-based colloidal nanoparticles for applications in targeted vaccine delivery

Khan, Muhammad Saad; Appak-Baskoy, Sıla; Yang, Celina; Hong, Joohye; Chae, Jayoung; Ha, Hee-Jin; Lee, Sung-Jun; Tanaka, Masayoshi; Choi, Yonghyun; Choi, Jonghoon

doi:10.1039/d2na00795a

Cited by 13 publications

(6 citation statements)

References 166 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Mosquirix, a malaria vaccine, uses recombinant DNA technology and AS01 adjuvant, while Shingrix, a shingles vaccine, is FDA-approved for adults over 50. 44 LBNP systems containing ionizable amino lipids provide efficient, nontoxic DNA delivery for gene expression. 45 The first mRNA vaccines against the influenza viruses H10N8 and H7N9 were well tolerated and elicited strong humoral immune responses.…”

Section: Platformsmentioning

confidence: 99%

“…LBNP-based nucleic acid vaccines are in different stages of development, with a few that have been FDA-approved for various diseases. For example, Mosquirix, a malaria vaccine, uses recombinant DNA technology and AS01 adjuvant, while Shingrix, a shingles vaccine, is FDA-approved for adults over 50 . LBNP systems containing ionizable amino lipids provide efficient, nontoxic DNA delivery for gene expression .…”

Section: Lipid-based Nps As Cancer Vaccine Platformsmentioning

confidence: 99%

See 1 more Smart Citation

Lipid- and Polymer-Based Nanocarrier Platforms for Cancer Vaccine Delivery

Sunoqrot,

Abdel Gaber,

Abujaber

et al. 2024

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Cancer immunotherapy has gained popularity in recent years in the search for effective treatment modalities for various malignancies, particularly those that are resistant to conventional chemo-and radiation therapy. Cancer vaccines target the cancer-immunity cycle by boosting the patient's own immune system to recognize and kill cancer cells, thus serving as both preventative and curative therapeutic tools. Among the different types of cancer vaccines, those based on nanotechnology have shown great promise in advancing the field of cancer immunotherapy. Lipid-based nanoparticles (NPs) have become the most advanced platforms for cancer vaccine delivery, but polymer-based NPs have also received considerable interest. This Review aims to provide an overview of the nanotechnologyenabled cancer vaccine landscape, focusing on recent advances in lipid-and polymer-based nanovaccines and their hybrid structures and discussing the challenges against the clinical translation of these important nanomedicines.

show abstract

Section: Platformsmentioning

confidence: 99%

Section: Lipid-based Nps As Cancer Vaccine Platformsmentioning

confidence: 99%

Lipid- and Polymer-Based Nanocarrier Platforms for Cancer Vaccine Delivery

Sunoqrot,

Abdel Gaber,

Abujaber

et al. 2024

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

show abstract

“…Furthermore, the incorporation of liquid lipids has the potential to disturb the lattice arrangement of solid lipids, leading to the formation of anomalous crystalline cores within NLCs, thereby augmenting the drug loading capacity by increasing the available space 199,200 . By manipulating the proportion of liquid lipids while preserving the skeletal structure of NLCs can facilitate more accurate regulation of drug release kinetics 201 . Although the field is still young, the deployment of SLNs and NLCs encapsulating widely used cancer immune drugs and some mRNA products hold an encouraging potential for future studies.…”

Section: Lipid‐based Nps As Drug Delivery System In Cancer Immunotherapymentioning

confidence: 99%

“… 199 , 200 By manipulating the proportion of liquid lipids while preserving the skeletal structure of NLCs can facilitate more accurate regulation of drug release kinetics. 201 Although the field is still young, the deployment of SLNs and NLCs encapsulating widely used cancer immune drugs and some mRNA products hold an encouraging potential for future studies.…”

Section: Lipid‐based Nps As Drug Delivery System In Cancer Immunotherapymentioning

confidence: 99%

Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapy

Yang

Zhou

et al. 2023

MedComm

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have shown remarkable success in cancer treatment. However, in cancer patients without sufficient antitumor immunity, numerous data indicate that blocking the negative signals elicited by immune checkpoints is ineffective. Drugs that stimulate immune activation‐related pathways are emerging as another route for improving immunotherapy. In addition, the development of nanotechnology presents a promising platform for tissue and cell type‐specific delivery and improved uptake of immunomodulatory agents, ultimately leading to enhanced cancer immunotherapy and reduced side effects. In this review, we summarize and discuss the latest developments in nanoparticles (NPs) for cancer immuno‐oncology therapy with a focus on lipid‐based NPs (lipid‐NPs), including the characteristics and advantages of various types. Using the agonists targeting stimulation of the interferon genes (STING) transmembrane protein as an exemplar, we review the potential of various lipid‐NPs to augment STING agonist therapy. Furthermore, we present recent findings and underlying mechanisms on how STING pathway activation fosters antitumor immunity and regulates the tumor microenvironment and provide a summary of the distinct STING agonists in preclinical studies and clinical trials. Ultimately, we conduct a critical assessment of the obstacles and future directions in the utilization of lipid‐NPs to enhance cancer immunotherapy.

show abstract

“…Various techniques have been established to add functional moieties to the surface of LNPs, thereby enhancing the recognition of specific targets. The utilization of targeted modalities or cell membrane/extracellular vesicle hybrid systems is expected to boost the effectiveness of disease treatments while simultaneously enhancing targetability and intracellular delivery efficiency [ 128 , 129 ]. Active applications of technologies such as synthetic biology [ 130 , 131 ], which can engineer cell membranes to target tumors, and click chemistry [ 132 , 133 ], which can precisely conjugate cancer-targeting ligands to the surface of LNPs, are anticipated.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy

Han,

Lim,

Wang

et al. 2023

Nano Convergence

View full text Add to dashboard Cite

Cancer immunotherapy, which harnesses the power of the immune system, has shown immense promise in the fight against malignancies. Messenger RNA (mRNA) stands as a versatile instrument in this context, with its capacity to encode tumor-associated antigens (TAAs), immune cell receptors, cytokines, and antibodies. Nevertheless, the inherent structural instability of mRNA requires the development of effective delivery systems. Lipid nanoparticles (LNPs) have emerged as significant candidates for mRNA delivery in cancer immunotherapy, providing both protection to the mRNA and enhanced intracellular delivery efficiency. In this review, we offer a comprehensive summary of the recent advancements in LNP-based mRNA delivery systems, with a focus on strategies for optimizing the design and delivery of mRNA-encoded therapeutics in cancer treatment. Furthermore, we delve into the challenges encountered in this field and contemplate future perspectives, aiming to improve the safety and efficacy of LNP-based mRNA cancer immunotherapies. Graphical Abstract

show abstract

Lipid-based colloidal nanoparticles for applications in targeted vaccine delivery

Abstract: Bioactive molecules and drugs have been influenced by their solubility and administration route. In many therapeutic reagents, therapeutic performance is dependent on the physiological barrier in the human body and...

Cited by 13 publications

References 166 publications

Lipid- and Polymer-Based Nanocarrier Platforms for Cancer Vaccine Delivery

Lipid- and Polymer-Based Nanocarrier Platforms for Cancer Vaccine Delivery

Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapy

Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy

Contact Info

Product

Resources

About